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ABSTRACT
Objective To investigate whether vitamin D
supplementation can decrease the mortality and
morbidity of low birthweight infants in low income
countries.
Design Randomised controlled trial.
Setting Large government hospital in New Delhi, India.
Participants 2079 low birthweight infants born at term
(>37 weeks’ gestation).
MainoutcomemeasuresPrimaryoutcomewasadmission
to hospital or death during the first six months of life.
Main secondary outcome was growth.
Interventions Weekly vitamin D supplements for six
monthsatadoseofonerecommendednutrientintakeper
day(35 µg/week).Infantswerevisitedweeklyathomefor
observed supplementationand were broughtto the clinic
monthly for clinical examination and anthropometric
measurements.
Results Between group differences were not significant
for death or hospital admissions (92 among 1039 infants
in the vitamin D group v 99 among 1040 infants in the
placebo group; adjusted rate ratio 0.93, 95% confidence
interval0.68to1.29;P=0.68),orreferraltotheoutpatient
clinicformoderatemorbidity.VitaminDsupplementation
resultedinbettervitaminDstatusasassessedbyplasma
calcidiol levels at six months. In adjusted analyses,
vitamin D treatment significantly increased standard
deviation (z) scores at six months for weight, length, and
arm circumference and decreased the proportion of
childrenwithstuntedgrowth(lengthforagez score ≤2)or
with arm circumference z scores of 2 or less.
Conclusion A weekly dose of vitamin D resulted in better
vitamin D status and benefited the classic vitamin D
function of bone growth but did not decrease the
incidence of severe morbidity or death among young low
birthweight infants.
Trial registration ClinicalTrials.gov NCT00415402.
INTRODUCTION
Vitamin D is well known for its role in calcium meta-
bolism and bone health.
1 In addition, vitamin D is
active in the immune system.
2 Low plasma levels of
calcidiol, the accepted marker of vitamin D status, are
associated with increased infectious disease, especially
respiratory tract infections, in several populations,
3-5
including young Indian children.
6 Randomised con-
trolled trials of vitamin D supplements to improve dis-
ease resistance have shown no therapeutic benefit of
vitamin D for African patients with tuberculosis
7 and
no prophylactic benefit for infections among middle
aged American adults
8 or older British adults.
9 Vita-
min D supplements were associated with fewer seaso-
nal influenza infections in Japanese schoolchildren.
10
These trials were either small
810or carried out among
groups where vitamin D status was not measured
910or
where deficiency was mild.
78
A low plasma calcidiol level is widespread, even
among populations at low latitude. In Delhi, vitamin
D deficiency is common among women and children,
possibly as a result of limited exposure to sunlight and
highsmoglevels.
1112Lowbirthweightisalsocommon
in Indiaandtheseinfantsare at highriskof respiratory
tract infections and other morbidity.
13 Low cost inter-
ventions such as improving vitamin D status are
needed to improve the health and survival of these
infants. We hypothesised that vitamin D supplements
would decrease mortality and severe morbidity of low
birthweight infants born at term in India. We studied
thisgroupinpartbecauseoftheirhighmortalityandin
partbecausethestudyhospitalroutinelyprovidesvita-
min D supplements to preterm infants and we wanted
to know whether to extend the practice to this other
group of at risk infants.
METHODS
We carried out an individually randomised, double
blind, placebo controlled trial of weekly vitamin D
supplementation of Indian infants for the first six
monthsoflife:theDelhiInfantVitaminDSupplemen-
tation (DIVIDS) study. The study took place from
March 2007 to July 2010.
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sions or death. Secondary outcomes were anthropo-
metric measurements and vitamin D status at
6 months of age.
Recruitment
Infants born at Safdarjung Hospital, New Delhi were
eligible if they were singleton; their gestation was
37weeksormore,asdefinedbythelastmenstrualper-
iod; they had a birth weight between 1.8 and 2.5 kg;
they were aged less than 48 hours; they lived within a
15 km radius of Safdarjung Hospital; and their parents
gave written or thumb print informed consent. Exclu-
sion criteria were severe congenital abnormalities,
morbidity severe enough to result in death before age
7 days, intention to live outside the catchment area
before the infant reached 6 months of age, or lack of
consent. No families were included twice.
Safdarjung Hospital is a large government hospital
inSouthDelhigivingsubsidisedmedicaltreatmenttoa
low to middle income population. The hospital has
20000 deliveries per year, with about 20% resulting
in low birthweight infants.
Randomisation and masking
Asimplerandomisationlistwithoutblockingwascom-
puter generated and held by the data safety and mon-
itoring board only. At enrolment the infants were
randomised to receive each week, starting at 7 days of
age and continuing to 6 months (maximum of 25
doses), either 35 µg (1400 IU) granulated vitamin D3
(cholecalciferol), which is the Food and Agriculture
Organization/World Health Organization recom-
mended nutrient intake of 5 µg (200 IU) per day,
14 or
an identical appearing and tasting placebo (both pre-
paredbyCadillaPharmaceuticals,Gujarat,India).The
ethicscommitteedidnotpermituseofalargervitamin
D dose. The data safety and monitoring board indivi-
duallylabelledthesachetscontainingvitaminDorpla-
cebo crystals with the participant identification
number. The study team remained blinded to treat-
ment allocation until the primary and growth out-
comes had been analysed.
Administering of supplement and compliance
The infants received the supplement or placebo dis-
solved in a small amount of expressed breast milk (or
other milk for rare non-breastfed infants). Hospital
nurses trained the mothers in how to express breast
milk before discharge. Because breast milk was used
for dosing, weekly supplementation began when the
infantwas7daysold.Supplementswereusuallyadmi-
nistered directly at the infants’ home by field workers,
whorecordedcompliance.Incasesofplannedtempor-
ary absence from home, the parents received the
sachets in advance and compliance was recorded as
the number of empty sachets returned. In about 10%
ofcases,familiesplannedpermanentabsenceandwere
given the sachets to take with them. For these partici-
pants compliance and morbidity were recorded by
weekly mobile phone calls; this is reflected in the dif-
ferent completion rates for morbidity and anthropo-
metric measurements.
Participant follow-up
At recruitment at Safdarjung Hospital, we used stan-
dardised questionnaires to collect demographic and
socioeconomic data of the families and anthropo-
metric measurements of the infants. Fieldworkers
recorded infant morbidity at weekly home visits
using a pretested questionnaire. They were trained to
identify conditions requiring clinical attention and to
advise parents to take their infants to hospital.
Parents brought the infants to the hospital at ages 6,
10, 14, 18, 22, and 26 weeks for anthropometric mea-
surements, clinical examination by a doctor, and stan-
dard vaccinations according to age. Standardised
questionnaires were used to collect information on
the overall health of the infants in the past month as
well as specific symptoms in the past week. Informa-
tion was also collected on the infants’ diet, including
breastmilk,otherdrinks,foods,orsupplements.Expo-
suretosunlightwasestimatedastheaveragenumberof
days outside multiplied by hours per day reported at
each clinic visit, and recorded as “usual” exposure.
The parents were encouraged to bring their infants
to Safdarjung Hospital whenever ill. Doctors not con-
nected with the study decided whether or not to admit
theinfantstohospital.Illnessesdetectedatbothsched-
uled and unscheduled visits were recorded along with
information on where the infant was seen (inpatient or
outpatient), diagnosis, treatment, duration of hospital
stay if applicable, and outcome.
Anthropometric measures
The infants’ weightwas measuredto within 10 g(Pres-
tige Baby Weighing Scale, HM-008A; Hardik Medi
Tech, Delhi, India), length to the nearest 0.1 cm using
aninfantometer(SumitSurgicals,Delhi),andheadcir-
cumference and mid-upper arm circumference to the
nearest0.1 cm using non-stretchable tapes(Chasmors,
London). Maternal weight was measured to within
100 g and mid-upper arm circumference to within 0.1
cm. Maternal height was measured at the first sched-
uled postnatal clinic visit at six weeks. All anthropo-
metric data were collected in duplicate and the mean
infant values were converted to z scores using the
WHO growth reference.
15 As flagged values, indicat-
ing low scores, were common in this low birthweight
population we corroborated these against paper
records and infant growth trajectories. We calculated
the technical error of measurement using standard
methods about every six months, which was within
acceptable ranges.
16
Vitamin D status
Forlogisticalreasonsblood samplingforvitaminD sta-
tus at six months began in November 2008. Venous
blood (5 mL) was collected in lithium heparin vacutai-
ners and processed within two hours of collection.
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by radioimmunoassay using 25OH Vitamin D Total
Assay kits (Diasorin; Stillwater, MN). We used the
mean of duplicate assays. The interassay coefficients of
variation for both high and low control sera were 7%
and values for external standards were within accepta-
ble ranges. We classified vitamin D status as adequate
(>50 nmol/L), mildly deficient (25-50 nmol/L), or
severely deficient (<25 nmol/L).
17
Statistical analyses
Data were double entered in Microsoft Access and
crosscheckedbeforeimportingintoStata11.1forana-
lysis. The primary outcome—incidence of death or
hospital admission—in all children (intention to treat)
wasanalysedbytreatmentgroupusingWeibullregres-
sion with gamma shared frailty to account for multiple
admissions within child. To avoid repeat counting of
the same illness we considered infants to be at risk
againthreedaysafterdischargefromapreviousadmis-
sion for severe morbidity.
Secondaryoutcomesofthestudyweredifferencesin
vitamin D status and in weight for age, length for age,
mid-upper arm circumference, and head circumfer-
ence for age z scores, all measured at 6 months of age.
Wealsoanalysedasabinaryvariabletheoccurrenceof
any admission to hospital or death. Linear regression
was used to analyse these outcomes.
We defined any severe morbidity as death, hospital
admission, or outpatient visits with diagnoses selected
based on clinical judgment that represented severe
illness: pneumonia, persistent diarrhoea, dysentery,
severe fever, severe protein energy malnutrition, ear
infections, meningitis, and septicaemia. We analysed
the incidence of severe morbidities as for the primary
outcomeusingWeibullregressionwithgammashared
frailty, again requiring a gap of at least three days
between events.
Initialanalysescomparedthecrudeeffectofvitamin
Dsupplementationwithplacebo.Baselinecharacteris-
ticswere thenassessedfortheirassociationwithlossto
follow-up. We then carried out analyses adjusting for
all characteristics associated with missing data (assum-
ing data were missing at random) and additionally
adjusted for infants’ sex, quintiles of socioeconomic
status, and quintiles of exposure to sunlight. We also
assessed the effect of season—summer (April to June),
monsoon (July to September), and winter (October to
March)—foritsrelationwithincidencerates.Socioeco-
nomicstatuswasgeneratedusingprincipalcomponent
analysis
18 of household demographics, housing mate-
rials, and material possessions. As the true dates for
stopping breast feeding were not known, we used
Kaplan-Meier estimates to obtain the median dura-
tions of both exclusive (breast milk and nothing else)
and predominant (breast milk plus non-nutritive
liquids only) breast feeding, by using the midpoint
between the dates the infant was known to have still
been breast feeding exclusively or predominantly
and was known to have stopped this feeding pattern.
Sample size
The sample size of 1000 per treatment arm was based
on estimates of mortality from two studies in Delhi: a
hospital audit showing a neonatal mortality rate of
4.5% oflive births,with low birthweightinfantscontri-
buting 84.5% of the deaths,
19 and a controlled trial
showing a mortality rate of 2.6% between 1 and
9 months of age in the control group.
20 A hospital
admission rate of 20% within the first six months of
life was estimated from a study of low birthweight
term infants in Brazil.
21 We estimated the combined
rate of mortality (about 6% based on the Delhi data)
or admission to hospital (20% based on the Brazilian
data)before6monthsofageintheplacebogroupofthe
studypopulationas26%.Ata5%significancelevel,we
needed 903 infants per treatment arm to detect a 25%
reductioninthecombinedrateofmortalityandadmis-
sion to hospital with 90% power. We allowed for 10%
loss to follow-up and aimed to recruit 1000 infants per
treatment group.
RESULTS
Figure 1 shows the flow of participants through the
study.Theaddressesof138of2079(6.6%)infantsallo-
cated to treatment were not found and the parents
could not be contacted as the poorest families lacked
mobilephones.Afurther413(19.9%)infantswere lost
to follow-up, primarily because many from outlying
rural areas returned to their homes after obtaining
healthcare despite saying at recruitment that they
intended to stay in the area for at least six months.
Two hundred and seven (10%) infants were
Allocated to placebo (n=1040) Allocated to vitamin D (n=1039)
Received placebo (n=957) Received vitamin D (n=969)
Completed 6 months’ morbidity follow-up
  (n=745; 72% of randomised, 78% of dosed)
Completed 6 months’ anthropometry
  (n=648; 62% of randomised, 68% of dosed)
Completed 6 months’ morbidity follow-up
  (n=744; 72% of randomised, 76% of dosed)
Completed 6 months’ anthropometry
  (n=634; 61% of randomised, 65% of dosed)
Assessed for eligibility (n=5512)
Randomised (n=2079)
Address not found; no dose given (n=65)
Died before dose (n=5)
Died (n=15)
Lost to follow-up (n=210):
  Moved (n=196)
  Withdrew (n=14)
Lost to follow-up (n=203):
  Moved (n=195)
  Withdrew (n=8)
Address not found; no dose given (n=73)
Died before dose (n=10)
Excluded (n=3433):
  Preterm (n=133)
  Birth weight (n=259)
  Address out of area after birth (n=2966)
  Congenital abnormalities (n=21)
  Severe illness (n=7)
  Refused (n=47)
Died (n=9)
Fig 1 | Flow of participants through study
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but morbidity and visits to clinics or hospital were col-
lected by weekly mobile phone calls so that data were
available for the primary outcome for 72% of those
initially randomised but anthropometric data for only
62%. Losses to follow-up were biased to poorer
families; those lost to morbidity follow-up were more
likely to be from smaller and nuclear families, to have
less well educated parents, and to be from the lowest
quintiles for socioeconomic status (see web extra
table 1). Similar results were found for those missing
anthropometric data at follow-up. A larger number
had missing results for plasma calcidiol levels owing
to the late start of blood collection and refusals; factors
associated with missing values were low quintile for
socioeconomic status, low maternal education, low
paternal education, and nuclear family type.
Participants in the two treatment arms were similar
at baseline (table 1). As inclusion criteria included an
absolute birthweight cut-off point, the groups com-
prised more girls than boys. The population was fairly
poor, with low education, low incomes, and crowded
homes. Breast feeding was almost universal: the med-
ian duration of exclusive breast feeding was 15 weeks
and of predominant breast feeding was 20 weeks and
wassimilarinbothtrialarms(Pvaluesforlogranktests
of differences were 0.58 for exclusive breast feeding
and 0.50 for predominant breastfeeding). Themedian
reported exposure to sunlight in a four week period
was 10.8 hours (interquartile range 3.8 to 25.9), and
wassimilarinbothtrialarms.Theproportionofinfants
receiving at least 23 doses was similar in both trial
arms: 748/1039 (72%) in the vitamin D arm and 760/
1040 (73%) in the placebo arm.
Infantsinthe vitaminDtreatmentgrouphadsignifi-
cantly higher plasma calcidiol levels at six months
(table 2); crude mean difference 19.00 nmol/L (95%
confidence interval 14.7 to 23.5; P<0.001). After
adjustment for sunlight exposure and for factors asso-
ciated with not having a result for calcidiol, the
adjusted mean difference was 18.7 nmol/L (14.2 to
23.5; P<0.001). In the vitamin D group fewer infants
had severe vitamin D deficiency (<25 nmol/L); never-
theless, almost half the infants in this group did not
have adequate vitamin D status (>50 nmol/L) despite
210/219 (93%) receiving 23 or more doses of vitamin
D. As rickets becomes more apparent once children
start to walk, only one child, in the placebo group,
was found to have bone pain but no other symptoms
of rickets on examination at six months.
Table 1 |Characteristics of infants receiving vitamin D
supplementation or placebo. Values are numbers
(percentages) unless stated otherwise
Characteristics
VitaminDgroup
(n=1039)
Placebo group
(n=1040)
Girls 551 (53) 558 (54)
Mean (SD) birth weight (kg) 2.2 (0.2) 2.2 (0.2)
Mean (SD) maternal age (years) 23.5 (3.3) 23.5 (3.5)
Mean (SD) maternal body mass
index*
21.2 (3.0) 21.0 (2.9)
Religion:
Hindu 913 (88) 915 (88)
Muslim 108 (10) 103 (10)
Other 18 (2) 22 (2)
Family type:
Nuclear 462 (44.5) 466 (45)
Joint 379 (36.5) 376 (36)
Extended 198 (19) 198 (19)
Family size:
3-5 576 (55.5) 564 (54)
6-9 354 (34) 361 (35)
>10 109 (10.5) 115 (11)
Mean (SD) average No of family
members
5.9 (0.9) 5.9 (0.9)
Maternal education:
None 224 (22) 221 (21)
Primary 460 (44) 478 (46)
Secondary 283 (27) 281 (27)
College or university 72 (7) 60 (6)
Paternal education:
None 105 (10) 103 (10)
Primary 403 (39) 450 (43)
Secondary 419 (40) 394 (38)
College or university 112 (11) 93 (9)
Paternal occupation:
Unemployed or student 28 (3) 26 (2.5)
Employed 917 (88) 910 (87.5)
Self employed 94 (9) 104 (10)
Maternal occupation:
Employed 27 (3) 28 (3)
Unemployed or housewife 1012 (97) 1012 (97)
Asset index score (quintiles):
Lowest 213 (20.5) 203 (20)
Low 214 (21) 202 (19)
Middle 208 (20) 208 (20)
High 191 (18) 225 (22)
Highest 213 (20.5) 202 (19)
*Available for only 479 women in vitamin D arm and 469 women in
placebo arm.
Age (months)
No at risk
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Fig 2 | Kaplan-Meier plot of time to admission to hospital or
death of infants receiving vitamin D supplementation or
placebo
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admission or death. Twenty deaths occurred in the
vitamin D arm and 19 in the placebo arm but 15 were
beforeanysupplementation(fig1).Causesofdeathfor
thosedyingafterreceivingsupplementswerebasedon
hospital records (n=8), or on verbal autopsy for those
dying at home (n=16): pneumonia (n=7), septicaemia
(n=6), diarrhoea (n=4), fever (n=2), not feeding (n=1),
and unknown (n=4). Causes of death were known for
only two (one septicaemia and one pneumonia) of the
15 infants who died before supplementation. Rates of
death and admissionto hospital did not differ between
groups in either unadjusted or adjusted analyses
(table 3). Vitamin D had no significant effects on mor-
tality alone or on any severe morbidity in either unad-
justed or adjusted analyses. Similar effect estimates
were obtained when the analyses were repeated
excluding the 153 children who never received a
dose of vitamin D or placebo (see web extra table 2).
For the binary analysis of any hospital admission or
death, the unadjusted odds ratio was 0.92 (95% confi-
dence interval 0.67 to 1.26; P=0.59) and the odds ratio
adjusted for sex, quintile of socioeconomic status,
family type, and maternal education was 0.91 (95%
confidence interval 0.66 to 1.26; P=0.57).
Vitamin D supplementation was associated with
borderline increases in z scores for length, weight,
and arm circumference and a significant decrease in
head circumference (table 4). After adjustment for
infantsex,socioeconomicstatus,andfactorsassociated
with missing data, the strength of the benefits of vita-
min D for length, weight, and arm circumference was
increased,whereasthenegativeeffectonheadcircum-
ference was decreased. Similar results were obtained
when the anthropometric measures were analysed as
proportion with z scores of 2 or less.
DISCUSSION
InthisseverelyvitaminDdeficientpopulation,weekly
supplementation with the recommended daily allow-
anceofvitaminD3resultedinhighermeanplasmacal-
cidiol levels and a lower proportionof infants severely
deficient at 6 months of age compared with infants
givenplacebo.VitaminDtreatmentbenefitedtheclas-
sicvitaminDfunctionofbonegrowth,asevidencedby
greater length. However, supplementation did not sig-
nificantly benefit the disease resistance functions of
vitamin D as shown by the lack of difference between
groups in death or severe or moderate morbidity.
Strengths and limitations of the study
Thestudyhasseveralstrengths,includingitslargesam-
ple size, its successful blinding, its high and well docu-
mented compliance, its well balanced treatment
groups, and that it was carried out in a population
with documented poor vitamin D status, which
improved at the end of the trial in the vitamin D
group compared with the placebo group. The study’s
mainlimitationwasthelargelosstofollow-up,butcon-
trolling forfactors associatedwith missingdata didnot
alter the results. In addition, although the death rate
was similar to that used in the calculations of sample
size, inpatient admissions were much lower so power
was reduced and the confidence interval was wide and
includedtheoriginalestimateofa25%reductioninthe
primaryoutcome.Weestimatethat,withtheobserved
rateforthe primaryoutcomeinthe placebogroupand
the observed loss to follow-up, we would have needed
to recruit 1500 infants per group to detect the planned
25% reduction in mortality plus admission to hospital.
We increased the number of events in the secondary
analysis which included outpatient visits for severe
Table 2 |Effect of vitamin D supplementation on plasma calcidiol* levels at six months.
Values are numbers (percentages) unless stated otherwise
Variables
Vitamin D group
(n=216)
Placebo group
(n=237) P value
Mean (SD) calcidiol level (nmol/L) 55.0 (22.5) 36.0 (25.5) <0.001
Type of deficiency:
Severe (<25 nmol/L) 18 (8) 92 (39)
<0.001 Mild (10-20 nmol/L) 76 (35) 82 (35)
Adequate (>50 nmol/L) 122 (57) 63 (27)
*25-hydroxyvitamin D.
Table 3 |Incidence of admissions to hospital and death among infants up to 6 months of age and rate ratio of effect of vitamin D supplementation
Variables
Incidence rate* (95% CI)
Unadjusted rate
ratio (95% CI) P value
Adjusted† rate
ratio (95% CI) P value
Adjusted‡ rate
ratio (95% CI) P value
Vitamin D group
(n=1039)
Placebo group
(n=1040)
Hospital admission or death:
No of events/No of children 92/85 99/88 ————— —
Rate/child year 0.22 (0.18 to 0.27) 0.23 (0.19 to 0.29) 0.93 (0.68 to 1.27) 0.64 0.93 (0.68 to 1.27) 0.63 0.98 (0.70 to 1.38) 0.92
Death:
No of children 20 19 ————— —
Rate/child year 0.048(0.031to0.077) 0.045(0.029to0.074) 1.05 (0.56 to 1.98) 0.87 1.05 (0.56 to 1.97) 0.88 1.97 (0.74 to 5.28) 0.18
Any severe morbidity:
No of events/No of children 174/147 207/177 ————— —
Rate/child year 0.41 (0.35 to 0.49) 0.49 (0.42 to 0.57) 0.84 (0.67 to 1.06) 0.14 0.84 (0.67 to 1.05) 0.12 0.87 (0.69 to 1.09) 0.23
*Total person time in vitamin D group was 419 child years and in placebo group it was 422 child years.
†Adjusted for sex, quintile of socioeconomic status, family type, and maternal education.
‡Adjusted for sex, quintile of socioeconomic status, family type, maternal education, exclusive breastfeeding status, exposure to sunlight, and season: n=930 in vitamin D arm and n=881 in
placebo arm.
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in part for logistical reasons such as lack of beds in this
crowded hospital. Even with this larger number of
events, vitamin D supplementation was associated
with no significant benefit. This, together with the
near superimposition of the Kaplan-Meier curves for
rates of hospital admission or death in the two groups,
suggests that it would take a large sample size in this
population to detect a statistically significant benefit of
vitamin D supplementation that is unlikely to be of
biological importance.
Effects on anthropometric measures
The significant benefit of vitamin D supplements for
theselowbirthweightinfantsonstunting,underweight,
and low arm circumference is an important finding.
Stunting is common in many low income populations,
startsearlyinlife,andislargelyirreversible.
22Stunting
hasalsoproveddifficulttoprevent,possiblybecauseof
the large number of related nutritional, infectious,
social, and environmental factors.
The borderline negative effect of vitamin D on head
circumference is difficult to explain, especially when
other anthropometric measures were increased.
Although it is possible that vitamin D promoted long
bone growth at the expense of head and brain devel-
opment, this seems unlikely given that maternal vita-
min D status was positively associated with head
circumferenceinaprospectivestudy
23andthatthelim-
ited evidence on vitamin D and brain functions indi-
cates that it is deficient, not supplemental, vitamin D
that may be a problem.
24 Therefore, we conclude that
the slightly lower head circumference was a chance
findingandthatwehavenoevidenceofadverseeffects
of vitamin D.
Comparisons with other studies
In spite of the many benefits of vitamin D for immune
functions measured in vitro,
2 and the benefits for all
causemortalityinmainlyelderlyparticipantsrecruited
to trials of vitamin D for other outcomes,
25 clinical
trials of vitamin D for the prevention or treatment of
infectious disease have shown little benefit. A recently
published trial among young Afghan children
26 found
a benefit for prevention of recurrent pneumonia of a
single large dose of vitamin D. Vitamin D status was
not measured, although previous work in the area
showed it was likely to be poor, and the improvement
invitaminDstatusaftersupplementationwasnotmea-
sured. Trials showing no effect of vitamin D supple-
mentation on infections were done in mildly vitamin
D deficient populations.
7-9 Our study extends current
knowledgebyshowingalackofbenefitamongapopu-
lation where severe vitamin D deficiency was docu-
mented as highly prevalent and where supplements
resulted in higher vitamin D status.
Potential reasons for different effects on primary and
secondary outcomes
It is possible that different amounts of vitamin D are
requiredforoptimisationofdifferentvitaminDdepen-
dent functions. Evidence shows that higher doses of
vitamin D are needed to improve responses to tuber-
culosis than are needed for prevention of bone pro-
blems, the basis for current recommended daily
allowances.
27 This could explain why the one recom-
mended daily allowance given to the infants in our
study improved growth but did not significantly affect
morbidityandmortality.Itisalsopossiblethatalarger
dose of vitamin D, such as used in the Afghan trial,
26
would have had even greater benefits on both growth
and morbidity. It was notable that the one recom-
mended nutrient intake dose left almost half the sup-
plementedinfantswithinadequatestatusatsixmonths.
Wewerenotpermittedbytheethicscommitteetousea
larger dose.
It is also possible that breast feeding, almost univer-
sal in our cohort, protected the infants against most
severe infections, which is why the benefits of vitamin
D were not seen. This is one difference between our
Table 4 |Effect of vitamin D supplementation on anthropometric z scores at age 6 months in infants receiving vitamin D
supplementation or placebo. Values are means (standard deviations), number in group, unless stated otherwise
Variables Vitamin D group Placebo group Unadjusted difference
(95% CI)
P value Adjusted difference*
(95% CI)
P value
Weight −1.51 (0.98), n=627 −1.60 (0.98), n=646 0.09 (−0.02 to 0.20) 0.096 0.12 (0.01 to 0.22) 0.026
Length −1.84 (0.98), n=620 −1.95 (0.99), n=638 0.11 (−0.001 to 0.022) 0.053 0.12 (0.02 to 0.21) 0.014
Weight/length −0.34 (1.17), n=620 −0.36 (1.16), n=637 0.02 (−0.11 to 0.14) 0.811 0.03 (−0.09 to 0.16) 0.615
Head circumference −0.91 (0.94), n=617 −0.77 (0.95), n=642 −0.14 (−0.25 to −0.04) 0.008 −0.08 (−0.17 to 0.01) 0.080
Arm circumference −0.49 (0.91), n=622 −0.59 (0.95), n=641 0.10 (−0.002 to 0.20) 0.055 0.11 (0.01 to 0.21) 0.033
No (%) with z scores ≤2:
Weight 190 (30) 206 (32) 0.93 (0.73 to 1.18)† 0.541 0.87 (0.68 to 1.12)‡ 0.270
Length 270 (44) 310 (49) 0.82 (0.65 to 1.02)† 0.073 0.73 (0.57 to 0.95)‡ 0.018
Weight/length 44 (7) 36 (6) 1.28 (0.81 to 2.01)† 0.294 1.16 (0.72 to 1.86)‡ 0.546
Head circumference 66 (11) 49 (8) 1.45 (0.98 to 2.14)† 0.059 1.29 (0.85 to 1.97)‡ 0.231
Arm circumference 25 (4) 43 (7) 0.58 (0.35 to 0.97)† 0.034 0.55 (0.33 to 0.93)‡ 0.026
*Adjusted for baseline anthropometric z score (except for arm circumference where birth arm circumference was used instead), sex, quintile of
socioeconomic status, family type, maternal education, exposure to sunlight, and breast feeding for more than six months.
†Unadjusted odds ratio (95% CI).
‡Adjusted odds ratio (95% CI).
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26 since the children in that
studywereolderandrecruitedataboutthesameageas
median breastfeeding cessation; furthermore, about
10% of their children had never breast fed.
Conclusions
VitaminDsupplementsofonerecommendednutrient
intake improved growth in this vitamin D deficient
cohort of low birthweight term infants but did not
decrease mortality and severe morbidity, although
the large loss to follow-up reduced power for this out-
come. Infant vitamin D status depends on maternal
status, particularly during pregnancy.
28 The low status
wefoundintheinfantssuggeststhatmotherswerealso
deficient and it would be worth investigating the ben-
efits for both maternal and infant health of providing
vitamin D supplements during pregnancy.
29 Improv-
ing the vitamin D status of such infants, through sup-
plementation or increased exposure of mothers or
infants to sunlight, might help reduce the prevalence
of stunting and its adverse short and long term conse-
quences. Trials should also investigate higher doses of
vitamin D to determine whether its benefits can be
further increased.
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